Connect with us

Press Release

ORC, The Dark Horse in OPEN Eco-Layout

Published

5 years ago

on

Scientific innovations are the driving force for times transformation. Following steam engines, electricity and computer, Blockchain has brought a new revolution to technology and industry of this era.

When it comes to the currently most-talked-about blockchain technology, the decentralized finance (DEFI) deserves a special mention.

As of June 2020, the daily value locked in DEFI has broken the record, now standing at 27.3 billion dollars. It has been nibbling away at the trillion-dollar digital currency market, growing continuously into a giant.

DEFI presents huge market dividends, attracting many industry pioneers to grasp the preemptive opportunities for participation.

OPEN – Bring a wider range of assets to DeFi

OPEN is right among them. OPEN Foundation has started the overall layout of DEFI industry since 2019. After prudent and comprehensive considerations, OPEN chose OnlyChain.

Based on its analysis of OC’s position ratio via its digital asset management company with BTC Grayscale as a benchmark, OPEN has long appreciated OC and set mind to build DEFI ecology on OC system.

Open Finance is a basket of open finance and currency protocol applications developed by OPEN Foundation on OC. Through the protocol matrix with strong composability, it aims to realize a huge financial machine that can run and evolve by itself to replace the current economic operating mode and become a decentralized full-domain world bank.

OPEN is the first team to propose and practice protocol matrix concept in the industry. Its mature and supporting DEFI infrastructure provides one-stop decentralized financial solutions for global users and a unified liquidity space to serve open finance of the future.

Open Swap – Decentralized Exchange

Asset trading and clearing are important parts of traditional economic activities. It is Open Swap that assumes the above responsibilities in the OPEN system.

Open Swap delivers one-stop on-chain trading services for users based on its three core technologies and 20000+ TPS. The transfer speed speaks for itself.  Also, the underlying operating system of OC does make Open Swap extremely competitive in processing large and low-frequency transactions, providing users with smooth on-chain trading experiences.

Open Lend – Hybrid Lending Market

Open Lend benchmarked against the lending and financial derivative issuance in the traditional economic activities can automatically calculate interest rates based on supply-demand change.

This benefits borrowers and lenders, making up for the opportunity cost of holding assets in an open financial network and getting rid of the fixed interests from the traditional financial market.

Open Stable – Asset Protocol Aggregation Platform

Open Stable is the center part of OPEN, allowing users to generate the stable assets OUSD (i.e. stablecoin asset protocol) from the secured assets.

OUSD is encrypted assets softly pegged to US dollars as asset collateral. It provides excess backed assets for users so as to effectively withstand vicious inflation.

And thanks to the technical advantages of OC, Open Stable enjoys high-speed asset transfer and delivery.

Open Link Oracle

OpenLink is the first distributed oracle on OC.

It is a vehicle that captures the value of Open Finance and OnlyChain ecosystem. It has defined and realized a new on-chain price generation and digital value capture plan to fix interoperability issues for the smart contract, which significantly enables it to be applied in finance, insurance, supply chain and many other industries.

Since all full eco-applications in OPEN financial system are built on OC, the above applications are exclusively confined to it. However, there exists a shortage in asset diversity on OC. So, how to achieve OC’s interoperability with other blockchains to expand the Open financial ecosystem?

ORC – An ultimate solution to blockchain interoperability.

Open Reactor

Open Reactor – Cross-chain protocol

Open Reactor (ORC) is the first decentralized cross-chain solution on OC system and also the exclusive cross-chain protocol in OPEN system. It serves as a window for financial data and value exchange with external blockchains.

The core mechanism of ORC cross-chain solution is OrcVM, through which users can use BTC and ETH to generate OBTC and OETH on OnlyChain at 1:1 if asset security is guaranteed. Owing to the high-performance blockchain network of OC, users enjoy extremely low handling fees and high transaction speed.

ORC also allows users to transfer digital assets from OC system to other blockchain networks so that on-chain assets can be freely flowed, interacted and aggregated between different blockchains, thus bringing the entire cryptocurrency market back to its root.

The ORC cross-chain solution can be applied to any sub-application in OPEN system. That’s to say, in the years to come, ORC will be the exclusive channel for OPEN sub-protocol to expand its use scope and interact with other public chains. Its importance is beyond any doubt!

The financial sector is a pioneer in exploring the application of blockchain technology, with different institutions having varied blockchain-based layouts and applications. But there also exist some urgent problems of fragmentation.

ORC can realize asset, information and trade interconnectivity and collaboration between different blockchains, which provides broader imagination space for Blockchain’s further application in the financial sector.

ORC Value Analysis 

  1. Provide OPEN with a variety of practical cross-chain assets to make sub-protocol matrix connected.

OBTC and other cross-chain assets acting as a cohesive layer will run throughout the entire open financial ecology to make closer interactions between various sub-protocols, thus achieving a huge and autonomous DEFI ecosystem.

  • Integrate value of BTC and other mainstream digital assets into OC system for OC value expansion.

Relying on the digital token of Open Reactor, ORC will bring the value of Bitcoin and Ethereum into OC network so that asset liquidity of more public chains can be locked into it.

  • Offer an interactive channel between various OPEN applications and other public chains to expand the ecological layout.

ORC allows users to generate OBTC with BTC. These cross-chain assets can be uses as trade varieties, lending products and synthetic asset reserve resources between Open Swap, Open Lend and OpenStable, which immensely diversify assets in OPEN and promote their operation and deployment on the whole ecosystem.

  • Address problems existing in information interaction, asset transfer and business collaboration between the independent public chains and consortium chains of different industries, like banking, securities, insurance and real estate.

The financial sector is a pioneer in exploring the application of blockchain technology, with different institutions having varied blockchain-based layouts and applications. But there also exist some urgent problems of fragmentation.

ORC can realize the asset, information and trade interconnectivity and collaboration between different blockchains, which provides broader imagination space for Blockchain’s further application in the financial sector.

  • Push ahead with the rapid establishment of global financial integration or regional economic integration.

Cross-chain enables value to flow between different blockchains. During this process, users, data and scenarios can be well linked to finally build a larger value ecosystem. If cross-chain technology grows into maturity, blockchain in the future will become infrastructures like today’s highways, water and electricity supplies. This will greatly facilitate the free flow of value and promote global financial integration.

Conclusion

If OPEN is a new self-evolving and self-sustaining decentralized financial empire, ORC cross-chain solution will be its “reform and opening-up policy.”  Only by embracing a bigger external world can we accelerate the rapid and stable development of ecology and build a “sun-never-set empire.”

About us

https://www.openfin.network/#/

About Author

Alex Jacob

Alex Jacob is a literature author. He was born in Chicago. Alex passion is writing news articles. He writes number of articles and published it.

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

FS-Elliott to Be Featured on Now We Know with Steve Guttenberg Airing March 14 on CNBC

Published

2 hours ago

on

March 13, 2026

By

Export, PA, United States, 13th Mar 2026 – The upcoming episode of Now We Know! with Steve Guttenberg, airing March 14, 2026 at 1pm ET on CNBC will feature FS-Elliott, a company specializing in the design and manufacturing of high-performance centrifugal air and gas compressors.

The segment provides viewers with a behind-the-scenes look at the engineering and precision required to produce industrial equipment that supports manufacturing, energy production, and critical infrastructure worldwide. Through advanced technology and meticulous design, FS-Elliott’s compressors help power operations across a wide range of industries.

From reliability and efficiency to long-term performance, the episode highlights the role that specialized equipment plays in keeping industrial systems running smoothly.

By showcasing FS-Elliott’s work, Now We Know! sheds light on the often-unseen technologies that support modern industry. The series continues its mission to reveal the innovation and expertise behind the systems that drive everyday life.

About Now We Know!

Hosted by actor, author, and businessman, Steve Guttenberg, this unique platform inspires the next generation of knowledge seekers and viewers around the country. Each episode features up to four industry experts who provide their own unique perspective on the topic at hand via a 6-8–minute segment produced by our team, bringing a fresh look at interesting narratives, moderated by the one and only Steve Guttenberg. 

Learn more at NowWeKnowTV.com

About FS-Elliott Co., LLC

FS-Elliott is a global leader in the engineering and manufacturing of oil-free, centrifugal air and gas compressors, with operations in over 90 countries. For over 60 years, FS-Elliott has combined a commitment to quality with advanced technology, enabling our customers to increase productivity and lower system operating costs. For more information, visit www.fs-elliott.com.

For more details, contact:

Now We Know! with Steve Guttenberg

(877) 546-9995

feature@nowweknowtv.com

nowweknowtv.com

SOURCE Now We Know! with Steve Guttenberg

All images courtesy of Now We Know! with Steve Guttenberg

 

Media Contact

Organization: Now We Know!with Steve Guttenberg

Contact Person: Media Relations

Website: https://nowweknowtv.com/

Email: Send Email

Contact Number: +18775469995

City: Export

State: PA

Country:United States

Release id:42579

The post FS-Elliott to Be Featured on Now We Know with Steve Guttenberg Airing March 14 on CNBC appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

CMS (867.HK/8A8.SG) : New Drug for Renal Anaemia Desidustat Tablets Approved in China

Published

3 hours ago

on

March 13, 2026

By

SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that on 13 March 2026, new drug for renal anaemia Desidustat Tablets (the “Product”) has been approved for marketing in China by the National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a novel, oral HypoxiaInducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in non-dialysis adult, Chronic Kidney Disease (CKD) patients.

The approval of Desidustat Tablets will further strengthen the Group’s overall layout in the field of nephrology, and synergize with the marketed innovative drug Velphoro (Sucroferric Oxyhydroxide Chewable Tablets, indicated for CKD hyperphosphatemia). Through the efficient linkage of nephrology expert resources and channel networks, the Group is expected to rapidly promote the large-scale clinical application of Desidustat Tablets, providing differentiated treatment options for Chinese CKD patients with renal anaemia and making a positive contribution to the Group’s performance.

More information about Desidustat Tablets and Renal Anaemia

As a novel oral HIF-PHI, the Product’s mechanism of action promotes erythropoiesis through increasing endogenous erythropoietin, improving iron availability and reducing hepcidin. Its China Phase III clinical trial has demonstrated positive results. The primary endpoint of the haemoglobin (Hb) mean change from baseline to Week 7-9 has indicated that, Desidustat is more effective than placebo in increasing Hb level. Results from the extension study demonstrate that the Product can maintain Hb level within the target range over the long term with acceptable safety. In addition, the Product significantly reduces hepcidin levels and ameliorates iron metabolism disorders.

There is still a large unmet need in the treatment of anaemia in CKD patients in China. It is estimated that there are more than 120 million CKD patients in China[1]. Anaemia is one of the frequent complications of CKD, which exhibits a progressively increasing incidence with disease progression. A survey in China showed that the prevalences of anaemia in patients at CKD stage 1 to 5 were 22.0%, 37.0%, 45.4%, 85.1%, and 98.2%, respectively[2]. The target-achieving rate (the Hb level reaching the target value (110~120g / L)) has increased to 51.5% for haemodialysis CKD patients with anaemia[3], but is still only 8.2% for anaemia patients in non-dialysis CKD[4]. The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia.

Desidustat Tablets have been approved for marketing in India.

CMS INTERNATIONAL DEVELOPMENT AND MANAGEMENT LIMITED, a wholly-owned subsidiary of the Group, obtained an exclusive license for the Product from Zydus Lifesciences Limited (earlier known as Cadila Healthcare Limited) pursuant to a License Agreement with an effective date of 20 January 2020.

The Group adheres to its core strategy of “innovation-driven”, having established a tiered and multi-dimensional innovation product portfolio with abundant reserves: 7 new drugs have been approved for marketing, 6 are currently under marketing review, and nearly 20 projects are about to initiate or are progressing through clinical trials. Through a dual-engine innovation approach combining collaborative development and in-house R&D, the Group continuously enriches its innovative pipeline centered on first-in-class (FIC) and best-in-class (BIC) products, efficiently advancing clinical development and commercialization. Moving forward, CMS will remain clinical needs-driven to deliver more quality pharmaceutical solutions, steadfastly advancing toward the goal of becoming a specialty-focused, innovation-excellent multinational pharmaceutical enterprise.

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the Cardiovascular-Kidney-Metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.

Reference

1. ZhangL, WangF, WangL, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012, 379(9818):815-822. DOI: 10.1016/S0140-6736(12)60033-6

2. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2014 Revised Edition)[J]. Chinese Journal of Nephrology, 2014, 30(9): 712-716. DOI: 10.3760/cma.j.issn.1001-7097.2014.09.015

3. 19th CSN Critical Care & Blood Purification Congress, Chinese Medical Association (July 2-5, 2025)

4. Chinese Expert Consensus on the Diagnosis and Treatment of Renal Anemia (2018 Revised Edition)[J]. Chinese Journal of Nephrology, 2018, 34(11): 860-866. DOI: 10.3760/cma.j.issn.1001-7097.2018.11.012

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Website: https://web.cms.net.cn/en/home/

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Healing Beyond Surgery: Paramedical Tattooing Takes the Stage at Gather and Grow Cancer Event in Scottsdale

Published

3 hours ago

on

March 13, 2026

By

Scottsdale, AZ April 11, 2026 At the upcoming Gather and Grow conference, nationally recognized paramedical tattoo specialist Jayd Hernandez will lead an educational session highlighting how restorative tattooing is helping cancer survivors reclaim confidence, identity, and a sense of self after treatment.

Hernandez will present “Transformative Tattooing: Restoring Identity Through Paramedical Art” on Saturday, April 11, 2026, from 12:30 to 1:00 PM MST at the Hotel Valley Ho in Scottsdale.

The session explores how paramedical tattooing, including hyper realistic 3D areola restoration and scar camouflage, extends healing beyond surgery. Blending medical precision with artistic care, this specialized practice supports emotional recovery and body confidence for individuals navigating life after cancer.

Hernandez is a nationally recognized expert in 3D areola and nipple tattooing, specializing in hyper realistic restoration for breast cancer survivors following mastectomy. With more than a decade of experience and over 1,000 restorative procedures performed, her work is known for delivering results that are both visually lifelike and emotionally restorative.

She holds a National Provider Identifier, allowing eligible patients to pursue medical reimbursement for their procedures. Her trauma informed process and advanced aesthetic technique have led many reconstructive surgeons to refer patients directly to her studio for final stage care.

As the founder of one of the industry’s most comprehensive paramedical tattoo training programs, Hernandez has also trained a new generation of artists in medically responsible, client centered care. Her work has been recognized across both medical and beauty communities, helping bridge the gap between aesthetics and post surgical aftercare.

In addition to her presentation at Gather and Grow, Hernandez will attend the Oncology Clinical Updates Review and Renew in Sedona on April 11 and 12, 2026, where she has been invited as an Honorarium Attendee, reflecting growing recognition of her expertise within oncology adjacent and medical aesthetics communities.

Later this month, Hernandez is also scheduled to appear as a panel speaker on beauty business ownership at the Aveda Institute Phoenix, contributing her perspective on entrepreneurship within the beauty industry.

The Gather and Grow event brings together professionals, educators, and advocates focused on innovation, healing, and patient centered care in the cancer community.

For more information, visit:

https://jaydhernandez.com/

Media Contact

Organization: Jayd Hernandez

Contact Person: Jayd Hernandez

Website: https://jaydhernandez.com/

Email: Send Email

Contact Number: +14805765230

Country:United States

Release id:42543

The post Healing Beyond Surgery: Paramedical Tattooing Takes the Stage at Gather and Grow Cancer Event in Scottsdale appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us